Dynavax Technologies Corp
NASDAQ:DVAX

Watchlist Manager
Dynavax Technologies Corp Logo
Dynavax Technologies Corp
NASDAQ:DVAX
Watchlist
Price: 12.42 USD 0.49% Market Closed
Market Cap: 1.6B USD
Have any thoughts about
Dynavax Technologies Corp?
Write Note

Dynavax Technologies Corp
Accounts Payable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Dynavax Technologies Corp
Accounts Payable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Payable CAGR 3Y CAGR 5Y CAGR 10Y
Dynavax Technologies Corp
NASDAQ:DVAX
Accounts Payable
$7.1m
CAGR 3-Years
25%
CAGR 5-Years
-2%
CAGR 10-Years
4%
Abbvie Inc
NYSE:ABBV
Accounts Payable
$30.5B
CAGR 3-Years
12%
CAGR 5-Years
20%
CAGR 10-Years
18%
Gilead Sciences Inc
NASDAQ:GILD
Accounts Payable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Accounts Payable
$18.9B
CAGR 3-Years
153%
CAGR 5-Years
80%
CAGR 10-Years
35%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Accounts Payable
$4B
CAGR 3-Years
215%
CAGR 5-Years
112%
CAGR 10-Years
59%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Accounts Payable
$497.3m
CAGR 3-Years
5%
CAGR 5-Years
8%
CAGR 10-Years
27%
No Stocks Found

Dynavax Technologies Corp
Glance View

Market Cap
1.6B USD
Industry
Biotechnology

Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. The company is headquartered in Emeryville, California and currently employs 311 full-time employees. The company went IPO on 2004-02-19. The firm's products include HEPLISAV-B and CpG 1018. The HEPLISAV-B is indicated for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. HEPLISAV-B is a sterile solution for injection presented in 0.5 mL single-dose prefilled syringes. The firm also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. The firm is also engaged in developing CpG 1018 as a vaccine adjuvant through research collaborations and partnerships. HEPLISAV-B combines 1018, a toll-like receptor (TLR9) agonist adjuvant, and recombinant hepatitis B surface antigen (rHBsAg). The company is primarily focused on adjuvanted vaccines for coronavirus disease (COVID-19), plague, Tdap, seasonal influenza, universal influenza, and shingles.

DVAX Intrinsic Value
7.57 USD
Overvaluation 39%
Intrinsic Value
Price

See Also

What is Dynavax Technologies Corp's Accounts Payable?
Accounts Payable
7.1m USD

Based on the financial report for Sep 30, 2024, Dynavax Technologies Corp's Accounts Payable amounts to 7.1m USD.

What is Dynavax Technologies Corp's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
4%

Over the last year, the Accounts Payable growth was 129%. The average annual Accounts Payable growth rates for Dynavax Technologies Corp have been 25% over the past three years , -2% over the past five years , and 4% over the past ten years .

Back to Top